A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
List view / Grid view
Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
Japanese study has identified three previously unknown membrane proteins in ovarian cancer, using a new detection method consisting of nanotechnology and imaging techniques.
Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay
19 May 2023 | By CN Bio
A discussion of the recently published paper, “Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation-based Assay,” and how the field can produce more replicable experiments.
Chinese researchers use a glycosidic-bond-based mass-spectrometry-cleavable cross-linker to analyse proteins in vivo.
16 March 2023 | By Eurofins Discovery Services
In this on-demand webinar, we present the most advanced label-free technologies in identifying successful hit series for Hit-to-Lead and Lead-Optimization programs.
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
Researchers say a newly developed lab technique could spark a “paradigm shift” in biopharmaceuticals testing, promising to speed up drug discovery and development of protein-based drugs.